Compare CORT & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | TLX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | CORT | TLX |
|---|---|---|
| Price | $39.83 | $6.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $114.20 | $21.00 |
| AVG Volume (30 Days) | ★ 1.9M | 179.3K |
| Earning Date | 02-18-2026 | 01-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.87 | 0.04 |
| Revenue | ★ $741,172,000.00 | $664,225,558.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $29.62 | N/A |
| P/E Ratio | ★ $45.76 | $193.38 |
| Revenue Growth | 17.92 | ★ 55.35 |
| 52 Week Low | $32.99 | $6.34 |
| 52 Week High | $117.33 | $30.36 |
| Indicator | CORT | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 32.43 |
| Support Level | $38.00 | $6.94 |
| Resistance Level | $41.92 | $7.43 |
| Average True Range (ATR) | 2.02 | 0.24 |
| MACD | 0.93 | -0.07 |
| Stochastic Oscillator | 24.95 | 2.66 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.